Hainan Shuangcheng Pharmaceuticals Co., Ltd. engages in research and development, production, and sale of pharmaceutical injections, solid preparations, and raw materials in China and internationally. The company offers products for oncology and immune, alimentary canal, heart and cerebral, and vessels and metabolism. It also provides Bivalirudin, Epitifibatide, and Thymalfaxin for injection; Preg...
Hainan Shuangcheng Pharmaceuticals reported revenue of 276.76 million CNY for fiscal year 2025, up 58.9% from fiscal year 2024, and net income of 19.04 million CNY. In Q1 2026 (the quarter ended March 31, 2026) revenue was 48.44 million CNY, up 32.1% from a year before. Its largest business segment, Self-Produced Medicine Sales Business, brought in 72% of segment revenue in fiscal year 2025; Overseas Region was the largest region with 68%.
Figures from company filings; latest fiscal year ended December 31, 2025.
No profile data available.